The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.05 GBX | -.--% | -14.58% | -69.40% |
05-28 | NetScientific backs Wanda; Inspirit Energy wins deal | AN |
05-10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
The study is expected to be initiated in Q4 2022 and will be conducted by the Company's partner,
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-69.40% | 20.4M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |